Literature DB >> 11375382

Erythropoietin treatment of postural hypotension in anemic type 1 diabetic patients with autonomic neuropathy: a case study of four patients.

A S Winkler, S Landau, P J Watkins.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375382     DOI: 10.2337/diacare.24.6.1121

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  7 in total

Review 1.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

Review 2.  Neurologic complications of diabetes.

Authors:  Gerald A Charnogursky; Nicholas V Emanuele; Mary Ann Emanuele
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 5.081

3.  Current Management of Syncope: Treatment Alternatives.

Authors:  Carlos A. Morillo; Adrián Baranchuk
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-10

4.  Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice.

Authors:  Robert E Schmidt; Karen G Green; Dongyan Feng; Denise A Dorsey; Curtis A Parvin; Jin-Moo Lee; Qinlgi Xiao; Michael Brines
Journal:  Exp Neurol       Date:  2007-10-29       Impact factor: 5.330

Review 5.  Pure Autonomic Failure.

Authors:  Pariwat Thaisetthawatkul
Journal:  Curr Neurol Neurosci Rep       Date:  2016-08       Impact factor: 5.081

6.  Impaired orthostatic blood pressure stabilization and reduced hemoglobin in chronic kidney disease.

Authors:  Wenjin Liu; Lulu Wang; Xiaoqin Huang; Weichun He; Zongwei Song; Junwei Yang
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-08-30       Impact factor: 3.738

Review 7.  Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms.

Authors:  Sabine Eschlböck; Gregor Wenning; Alessandra Fanciulli
Journal:  J Neural Transm (Vienna)       Date:  2017-10-22       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.